Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

Summary

This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive RT and no distant metastasis or locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (RV001V).

Timeline

Start

2019-11-19

Primary completion

2022-04

Completion

2022-11

Drugs

Indications